Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09NNS
|
|||
| Former ID |
DNC001127
|
|||
| Drug Name |
Piretanide
|
|||
| Synonyms |
piretanide; 55837-27-9; Tauliz; Arlix; 4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid; Piretanido [Spanish]; HOE 118; Piretanidum [INN-Latin]; Piretanido [INN-Spanish]; UNII-DQ6KK6GV93; Arelix (TN); C17H18N2O5S; EINECS 259-852-9; Hoe-118; BRN 5633965; DQ6KK6GV93; 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid; 4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid; S 734118; S 73 4118; NCGC00016878-01; 3-(Aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-benzoic acid; Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H18N2O5S
|
|||
| Canonical SMILES |
C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3
|
|||
| InChI |
1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
|
|||
| InChIKey |
UJEWTUDSLQGTOA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 55837-27-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5518526, 7848697, 8152982, 11112792, 11467075, 11468195, 11486643, 12013328, 14876908, 29223930, 46507197, 47662472, 47885572, 48035310, 48259428, 48416447, 49699267, 49885994, 50100524, 56463166, 57322488, 78308364, 85174284, 85788564, 92125940, 93299945, 103141202, 103404067, 103913796, 104307607, 117630782, 121363611, 124799429, 125823618, 126665940, 129376135, 134222941, 134338818, 134340365, 135004355, 137006670, 144204212, 152034864, 160966084, 162175842, 163693597, 164764450, 170465869, 172892541, 175612126
|
|||
| ChEBI ID |
CHEBI:32015
|
|||
| SuperDrug ATC ID |
C03CA03
|
|||
| SuperDrug CAS ID |
cas=055837279
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 12 member 1 (SLC12A1) | Target Info | Blocker | [2], [3], [4] |
| KEGG Pathway | Salivary secretion | |||
| Pancreatic secretion | ||||
| Vibrio cholerae infection | ||||
| Pathwhiz Pathway | Kidney Function | |||
| Reactome | Cation-coupled Chloride cotransporters | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4742). | |||
| REF 2 | Peripheral and central antinociceptive action of Na+-K+-2Cl- cotransporter blockers on formalin-induced nociception in rats. Pain. 2005 Mar;114(1-2):231-8. | |||
| REF 3 | Rat NKCC2/NKCC1 cotransporter selectivity for loop diuretic drugs. Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):193-9. | |||
| REF 4 | Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986 Nov;40(5):587-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.